

Edwards & Angell LLP

101 Federal Street Boston, MA 02110 617.439.4444 fax 617.439.4170
www.EdwardsAngell.com

Date : November 12, 2003

From : Dianne M. Rees, Ph.D.

Fax : 617-439-4170

Direct : 888-951-3351

To : EXAMINER MAIHER
HADDAD

Fax : 703 746 8319

Direct :

Pages : 5

(including cover sheet)

If you received a partial delivery, please call Dianne Rees at 617-951-3351.

Re : Please consider the attached proposed claims in connection with
Attorney Docket No. 56804 (46342)
APPLICANTS: Itoh, et al.
U.S.S.N.: 10/019, 455
FILED (U.S.): December 28, 2001
Conf. No. 5636
FOR: NOVEL POLYPEPTIDE AND DNA THEREOF

Fax

Confidentiality Note : The documents accompanying this facsimile contain information from the law firm of Edwards & Angell, LLP, which may be confidential and/or privileged. The information is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile is strictly prohibited, and that the documents should be returned to this firm immediately. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.

seq

Attorney Docket No: 56804 (46342)
 Serial No. 10/019,455
 Filed: December 28, 2001

Page 1 of 4

Proposed Amendment to claims

Listing of Claims

VSE

Toge which Claims 1-24 (cancelled)

37/

25. (amended) An isolated polypeptide [containing] comprising the amino acid sequence represented by SEQ ID NO:24; [or containing (i) an amino acid sequence represented by SEQ ID NO:24, of which one or more amino acids are deleted, (ii) an amino acid sequence represented by SEQ ID NO:24, to which one or more amino acids are added, (iii) an amino acid sequence represented by SEQ ID NO:24, into which one or more amino acids are inserted, (iv) an amino acid sequence represented by SEQ ID NO:24, in which one or more amino acids are substituted by other amino acids, or (v) an amino acid sequence represented by SEQ ID NO:24 containing a combination of the modifications described in the above (i) to (iv), and having a biological activity substantially equivalent to that of the polypeptide having the amino acid sequence shown by SEQ ID NO:24]; or its amide or ester; or a salt thereof. human 110 aa

26. (amended) The polypeptide, its amide or ester, or a salt thereof, according to claim 25, which [contains] has the amino acid sequence represented by SEQ ID NO:6; [or which contains (i) an amino acid sequence represented by SEQ ID NO:6, of which one or more amino acids are deleted, (ii) an amino acid sequence represented by SEQ ID NO:6, to which one or more amino acids are added, (iii) an amino acid sequence represented by SEQ ID NO:6, into which one or more amino acids are inserted, (iv) an amino acid sequence represented by SEQ ID NO:6, in which one or more amino acids are substituted by other amino acids, or (v) an amino acid sequence represented by SEQ ID NO:6 containing a combination of the modifications described in the above (i) to (iv), and has a biological activity substantially equivalent to that of the polypeptide having the amino acid sequence shown by SEQ ID NO:6]. human 128 aa

Attorney Docket No: 56804 (46342)
Serial No. 10/019,455
Filed: December 28, 2001

Page 2 of 4

27. (amended) [The] An isolated polypeptide or its amide or ester, or a salt theroff, according to claim 25], which [contains] comprises the amino acid sequcnce represented by SEQ ID NO:26. \rightarrow mouse 110 all

28. (amended) The polypeptide or its amide or ester, or a salt therof, according to claim [26] 27, which [contains] has the amino acid sequence represented by SEQ ID NO:12. 128 mouse

29. (amcnded) [The] An isolated polypeptide or its amide or ester, or a salt thereoff, according to claim 25], which [contains] comprises the amino acid sequence rcpresented by SEQ ID NO:49. rat 110

30. (amcnded) The polypeptide or its amide or ester, or a salt therof, according to claim [26] rat 29, which [eontains] has the amino acid sequcnce represnted by SEQ ID NO:47. 128

31. (amcnded) An isolated nuclcic acid comprising a nucleic acid [having a base] sequence encoding the polypeptide [according to claim 25] comprising the amino acid sequence rcpresented by SEQ ID NO:6, 12, 24, 26, 47 or 49.

32. (amended) The isolated nuclcic acid according to claim 31, wherein the [base] nucleic acid sequence [encoding the polypeptide according to claim 25] is [the base sequence] represented by SEQ ID NO:23. \rightarrow 24 human 333

33. (amendcd) The isolated nucleic acid according to claim 31, wherein the [base] nucleic acid sequence [encoding the polypeptide according to claim 25] is [the base sequence] rcprcsented by SEQ ID NO:4. enc \rightarrow 6 human 384

Attorney Docket No: 56804 (46342)
Serial No. 10/019,455
Filed: December 28, 2001

Page 3 of 4

34. (amended) The isolated nucleic acid according to claim 31, wherein the base nucleic acid sequence [encoding the polypeptide according to claim 25] is [the base sequence] represented by SEQ ID NO:25. — ~~29~~ mouse 330

35. (amended) The isolated nucleic acid according to claim 31, wherein the base nucleic acid sequence [encoding the polypeptide according to claim 25] is the [base sequence] represented by SEQ ID NO:10. → ~~8~~ mouse 384

36. (amended) The isolated nucleic acid according to claim 31, wherein the base nucleic acid sequence [encoding the polypeptide according to claim 25] is [the base sequence] represented by SEQ ID NO:48. ~~rat~~ 330

37. (amended) The isolated nucleic acid according to claim 31, wherein the base sequence [encoding the polypeptide according to claim 25] is [the base sequence] represented by SEQ ID NO:46. ~~rat~~ 284
?

38. (amended) A pharmaceutical composition comprising the polypeptide, its amide or ester, or a salt thereof, [according to claim 25] which comprises the amino acid sequence represented by SEQ ID NO:6, 12, 24, 26, 47 or 49 and a pharmaceutical carrier.

Claims 39-40 (canceled).

41. (previously added) An isolated polypeptide wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 6, 12, 24, 26, 47 and 49.

42. (previously added) A recombinant vector comprising the DNA according to claim 31.

43. (previously added) A transformant transformed with the recombinant vector according to claim 42.

Attorney Docket No: 56804 (46342)

Serial No. 10/019,455

Filed: December 28, 2001

Page 4 of 4

44. (amended) A method for manufacturing the polypeptide or its amide or ester, or a salt thereof comprising the amino acid sequence represented by SEQ ID NO:6, 12, 24, 26, 47 or 49, [according to claim 25], which comprises culturing a transformant transformed with the recombinant vector comprising a DNA having a [base] nucleic acid sequence encoding the polypeptide [according to claim 25], and producing the polypeptide.

45. (currently amended) A reagent for screening a compound or its salt that promotes or inhibits the activity of the polypeptide comprising the amino acid sequence represented by SEQ ID NO:6, 12, 24, 26, 47 or 49 [or its salt according to claim 25], which comprises the polypeptide, its amide or ester, or a salt thereof, [according to claim 25, wherein the polypeptide comprises a label].

46. (currently amended) A kit for screening a compound or its salt that promotes or inhibits the activity of the polypeptide comprising the amino acid sequence represented by SEQ ID NO:6, 12, 24, 26, 47 or 49, [its amide or ester, or a salt thereof, according to claim 25, comprising] which comprises the polypeptide, its amide or ester, or a salt thereof [or its salt according to claim 25 and a reagent for measuring a biological activity of the polypeptide].

BOS2_351612.1